A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Inclusion Criteria: * invasive breast cancer * stage I-IIIA disease * ER, PR, Her2/neu-negative status * no prior treatment for breast cancer * age 18 years of greater * normal renal, liver function * normal hematologic status * ECOG Performance status 0, 1 * Evaluation by a surgeon to determine breast conservation eligibility * Women of childbearing potential must have a documented negative pregnancy test within 2 months of study trial entry and agree to birth control during the duration of the trial therapy * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Metastatic breast cancer * Inoperable breast cancer, including Stage IIIB and IIIC * Tumor size less than 1 centimeter * Prior surgery, systemic therapy, or radiotherapy for the current cancer * Hormone receptor-positive breast cancer * Her2/neu-positive breast cancer * Any concurrent condition which in the investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol * Pregnant or nursing women * Receipt of any investigational agents within 30 days prior to commencing study treatment